The Tyro3, Axl, and Mertk (abbreviated TAMs) family of receptor tyrosine kinases are implicated in a wide-spectrum of human cancers, in which TAM over-expression is clinically-associated with aggressive tumor grade and poor survival outcomes. The TamRx technology blocks the ligand binding and receptor-induced dimerization to inhibit TAM-mediated downstream activation of cellular processes favoring tumor growth and spreading. 

TamRx has a pipeline of small molecule inhibitors in development that uniquely target the TAM-Gas6 interface. The TamRx technology is advantageous due to its extracellular mode of action as well as the flexibility to target all three TAM family receptors. This novel family of small molecule pan-TAM inhibitors was developed by our primary scientific founders Ray Birge, PhD, William Welsh, PhD, and Youyi Peng, PhD, from Rutgers, The State University of New Jersey.

The TamRx pan-TAM inhibitors exhibit bifunctional activity by directly working as anticancer agents and indirectly promoting an anti-tumor immune response. Moreover, it is expected that the TamRx technology will work synergistically with immuno-oncology therapies, including newly-approved checkpoint inhibitors, in a wide variety of cancers.


Our technology is based on intellectual property exclusively licensed from Rutgers, The State University of New Jersey